Precision BioSciences, Inc.

As of August 21, 2025, Precision BioSciences, Inc. shows a mixed technical stance leaning mildly bearish, with positive momentum in MACD indicators but underperformance compared to the S&P 500, having a year-to-date return of 28.87% and a decline of 48.85% over the past year.

As of May 15, 2025, Precision BioSciences, Inc. is considered risky and overvalued due to poor financial metrics and a one-year stock performance of -48.85%, significantly underperforming the S&P 500's 17.14% return.

As of May 15, 2025, Precision BioSciences, Inc. is considered risky and overvalued due to a negative P/E ratio, low ROE of -83.23%, and poor stock performance, significantly underperforming the S&P 500.

As of February 3, 2025, the market trend is mildly bearish due to daily moving averages and Bollinger Bands, despite some bullish signals from the weekly MACD and KST, indicating a cautious outlook with short-term bearish tendencies.

As of March 2022, the management team of Precision BioSciences, Inc. includes President and CEO Matthew Kane and Chief Scientific Officer Derek Jantz, along with independent directors Kevin Buehler, Geno Germano, Raymond Schinazi, Shalini Sharp, and Tony Yao. They oversee the company's strategic direction and scientific advancements.

Precision BioSciences, Inc. is a genome editing company in the Pharmaceuticals & Biotechnology sector, currently reporting no net sales and a net loss of $21 million as of March 2025, with a market cap of $58.30 million. The company has a negative debt-equity ratio and return on equity, with no dividend yield.

As of Jun 18, Precision BioSciences, Inc. has a market capitalization of 58.30 million and reported net sales of 51.15 million with a net loss of 22.00 million over the latest four quarters. The balance sheet shows shareholder's funds of 56.39 million and total assets of 136.39 million.